These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 12010675

  • 1. Intensified induction followed by high-dose therapy with autologous peripheral blood stem cell support in poor-prognosis aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Choi SJ, Ryoo BY, Lee SS, Park Y, Kim BS, Kang YK.
    Haematologica; 2002 May; 87(5):555-7. PubMed ID: 12010675
    [No Abstract] [Full Text] [Related]

  • 2. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.
    Le Gouill S, Moreau P, Morineau N, Harousseau JL, Milpied N.
    Haematologica; 2002 Mar; 87(3):333-4. PubMed ID: 11869953
    [Abstract] [Full Text] [Related]

  • 3. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

  • 4. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.
    Bone Marrow Transplant; 2004 Nov 01; 34(9):781-6. PubMed ID: 15354206
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B, Schaefer W, Buell U, Osieka R.
    Bone Marrow Transplant; 2002 Jul 01; 30(2):103-11. PubMed ID: 12132049
    [Abstract] [Full Text] [Related]

  • 7. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
    Davidson KL, Devaney MB, Tighe JE, Rogers SY, Dunlop DJ, Mackie MJ, Thomas RV, Johnson PR, Scotland and Newcastle Lymphoma Group Study.
    Haematologica; 2003 Dec 01; 88(12):1366-71. PubMed ID: 14687989
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, Sureda A, Zuazu J, Marin J, Arranz R, Carreras E, Leon A, De Sevilla AF, San Miguel JF, Conde E, GEL/TAMO Spanish Group.
    Haematologica; 2003 Dec 01; 88(12):1372-7. PubMed ID: 14687990
    [Abstract] [Full Text] [Related]

  • 10. [Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients].
    Motomura S, Hashimoto C, Kodama F, Maruta A, Sakai R, Fujita H, Tomita N, Fujisawa S, Harano H, Koharazawa H, Fujimaki K, Kanamori H, Ishigatsubo Y.
    Rinsho Ketsueki; 2005 May 01; 46(5):350-7. PubMed ID: 16444968
    [Abstract] [Full Text] [Related]

  • 11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb 01; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
    Katipamula R, Porrata LF, Gastineau DA, Markovic SN, Moore SB, Greiner C, Burgstaler EA, Padley DJ, Winters JL.
    Bone Marrow Transplant; 2006 May 01; 37(9):811-7. PubMed ID: 16532018
    [Abstract] [Full Text] [Related]

  • 14. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM.
    J Clin Oncol; 2003 Nov 15; 21(22):4151-6. PubMed ID: 14615443
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T, Hirose A, Nakajima Y, Nakane T, Koh H, Takeoka Y, Nakamae M, Yamamura R, Nakamae H, Nakao Y, Mugitani A, Yagi T, Teshima H, Hino M.
    Gan To Kagaku Ryoho; 2006 Feb 15; 33(2):193-8. PubMed ID: 16484855
    [Abstract] [Full Text] [Related]

  • 17. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).
    Eur J Haematol; 2008 Mar 15; 80(3):227-35. PubMed ID: 18088400
    [Abstract] [Full Text] [Related]

  • 18. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
    Ruiz-Soto R, Sergent G, Gisselbrecht C, Larghero J, Ertault M, Hennequin C, Manson J, de Kerviler E, Briere J, Mounier N.
    Cancer; 2005 Dec 15; 104(12):2735-42. PubMed ID: 16284986
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evans' syndrome following autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Kamezaki K, Fukuda T, Makino S, Harada M.
    Clin Lab Haematol; 2004 Aug 15; 26(4):291-3. PubMed ID: 15279667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.